A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab

Katharine Batt, Bob G. Schultz, Jorge Caicedo, Christopher S. Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Michael Bullano

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab'. Together they form a unique fingerprint.

Medicine & Life Sciences